| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ... The Lancet 385 (9967), 517-528, 2015 | 3126 | 2015 |
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric … JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, ... Journal of clinical oncology 33 (6), 540, 2015 | 1896 | 2015 |
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells JN Kochenderfer, ME Dudley, SA Feldman, WH Wilson, DE Spaner, ... Blood, The Journal of the American Society of Hematology 119 (12), 2709-2720, 2012 | 1783 | 2012 |
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 JN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, ... Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 2010 | 1595 | 2010 |
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, ... Nature medicine 24 (1), 20-28, 2018 | 1231 | 2018 |
| ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile A Wiestner, A Rosenwald, TS Barry, G Wright, RE Davis, SE Henrickson, ... Blood 101 (12), 4944-4951, 2003 | 1096 | 2003 |
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia Y Herishanu, P Pérez-Galán, D Liu, A Biancotto, S Pittaluga, B Vire, ... Blood, The Journal of the American Society of Hematology 117 (2), 563-574, 2011 | 1040 | 2011 |
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410, 2009 | 848 | 2009 |
| T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma SA Ali, V Shi, I Maric, M Wang, DF Stroncek, JJ Rose, JN Brudno, ... Blood, The Journal of the American Society of Hematology 128 (13), 1688-1700, 2016 | 794 | 2016 |
| T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, ... Journal of Clinical Oncology 36 (22), 2267, 2018 | 701 | 2018 |
| Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia W Haso, DW Lee, NN Shah, M Stetler-Stevenson, CM Yuan, IH Pastan, ... Blood, The Journal of the American Society of Hematology 121 (7), 1165-1174, 2013 | 663 | 2013 |
| Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia RJ Kreitman, WH Wilson, K Bergeron, M Raggio, M Stetler-Stevenson, ... New England Journal of Medicine 345 (4), 241-247, 2001 | 644 | 2001 |
| Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies RJ Kreitman, WH Wilson, JD White, M Stetler-Stevenson, ES Jaffe, ... Journal of Clinical Oncology 18 (8), 1622-1636, 2000 | 551 | 2000 |
| IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells SA Rosenberg, C Sportès, M Ahmadzadeh, TJ Fry, LT Ngo, SL Schwarz, ... Journal of immunotherapy 29 (3), 313-319, 2006 | 506 | 2006 |
| In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. L Guedez, WG Stetler-Stevenson, L Wolff, J Wang, P Fukushima, ... The Journal of clinical investigation 102 (11), 2002-2010, 1998 | 490 | 1998 |
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 479 | 2015 |
| Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ... Cancer cell 31 (6), 833-843. e5, 2017 | 451 | 2017 |
| Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 G Kaur, M Stetler-Stevenson, S Sebers, P Worland, H Sedlacek, C Myers, ... JNCI: Journal of the National Cancer Institute 84 (22), 1736-1740, 1992 | 441 | 1992 |
| High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the … U Hegde, A Filie, RF Little, JE Janik, N Grant, SM Steinberg, K Dunleavy, ... Blood 105 (2), 496-502, 2005 | 416 | 2005 |
| Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia RJ Kreitman, MS Tallman, T Robak, S Coutre, WH Wilson, ... Journal of Clinical Oncology 30 (15), 1822, 2012 | 389 | 2012 |
